Narox (Etoricoxib)

Etoricoxib, the active ingredient in Narox, is a selective COX‑2 inhibitor presented as an oral dosage form for systemic use. It is used to manage pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain episodes, and gout in adult patients.

GNH USA supplies Narox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution.

Etoricoxib is indicated for several musculoskeletal and inflammatory conditions where COX‑2 mediated prostaglandin production contributes to pain and swelling.

- Osteoarthritis: reduces joint pain and inflammation, improving function and mobility. - Rheumatoid arthritis: alleviates joint swelling and stiffness, supporting daily activities. - Ankylosing spondylitis: diminishes spinal pain and stiffness, enhancing range of motion. - Acute pain: provides rapid relief of moderate to severe pain episodes. - Gout: decreases inflammatory pain during acute gout flares.

Etoricoxib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Gastrointestinal discomfort: includes dyspepsia, nausea, or abdominal pain. - Edema: mild swelling of the lower extremities.

Serious or Rare Side Effects: - Cardiovascular thrombotic events: increased risk of heart attack or stroke. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Gastrointestinal ulcer or bleeding: potentially life‑threatening hemorrhage. - Renal impairment: reduced kidney function or acute renal failure. - Anaphylaxis: rare but severe allergic reaction requiring immediate medical attention.

When prescribing Etoricoxib, clinicians should consider several safety precautions to minimize risk.

- Cardiovascular risk assessment: evaluate history of heart disease before initiating therapy. - Blood pressure monitoring: check and monitor hypertension regularly during treatment. - Renal and hepatic function: assess baseline kidney and liver status and repeat as needed. - Use in the elderly: start at the lowest effective dose and monitor for adverse effects. - Hypersensitivity caution: avoid in patients with known allergy to Etoricoxib or other COX‑2 inhibitors. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Etoricoxib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal and cardiovascular toxicity. - Selective serotonin reuptake inhibitors (SSRIs): elevated bleeding risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce antihypertensive effect and affect renal function. - Diuretics: potential for reduced diuretic efficacy and electrolyte imbalance. - Lithium: possible increase in lithium serum levels, requiring monitoring.